On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

Overall vaccine sales declined by 4% in 2024. Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while sales for its respiratory syncytial virus (RSV) vaccine Arexvy dropped by 51%.

GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.

Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

Also in vaccines, GSK’s star Shingles vaccine Shingrix saw sales drop 4% at constant exchange rates to 848 million pound sterling ($1.06 billion) in the last three months of 2024. An overall ...

Shingrix and our vaccines pipeline will contribute meaningfully in the medium and long term. Importantly, 2025 will see further additions to GSK's portfolio with five new product approvals ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...